Literature DB >> 5015032

Relative activities on and uptake by human blood platelets of 5-hydroxytryptamine and several analogues.

G V Born, K Juengjaroen, F Michal.   

Abstract

1. The specificity of platelet receptor sites for 5-HT uptake and for the rapid morphological change and aggregation was investigated with 5-hydroxy-tryptamine (5-HT) and seventeen analogues as well as with some antagonists of 5-HT.2. The analogues, with the exception of 5-hydroxy-N'N'-dibutyltryptamine, caused the rapid morphological change in platelets. In concentrations below those needed to produce the agonistic action (viz. 0.05-2.0 muM), these analogues themselves inhibited competitively the shape change caused by 5-HT.3. The velocity of change in shape caused by 5-HT was reduced in low Na media.4. Ten analogues produced platelet aggregation; three of these, viz. 5-methoxy-alpha-methyltryptamine, 5-hydroxy-alpha-methyltryptamine and 5-hydroxy-N'N'-diisopropyltryptamine), were approximately equipotent with 5-HT. Six analogues did not induce platelet aggregation.5. All the analogues which prevented the initial change in shape of platelets caused by 5-HT also inhibited its aggregating effect, apparently competitively with low K(i) values (0.02-1.6 muM).6. As with the inhibition of shape change, the inhibition of aggregation shows relatively low structural specificity of the receptor site.7. Methysergide was a potent inhibitor of shape change and aggregation (K(i) approximately 0.03 muM); imipramine was much less inhibitory (K(i) approximately 5-10 muM).8. Only one analogue (5-hydroxy-alpha-methyltryptamine) was taken up like 5-HT by platelets. All the other analogues inhibited the uptake of 5-HT by platelets (K(i)=0.2-2.7 muM).9. Methysergide was a weak inhibitor of 5-HT uptake (K(i) approximately 125 muM) whereas imipramine was very effective (K(i) approximately 0.3 muM).10. Our results show that the initial change in shape of platelets is required for and precedes aggregation. The structural specificity of the platelet receptor concerned with shape change and aggregation caused by 5-HT appears low whereas the uptake mechanism is a highly specific one. The uptake probably proceeds through more than one step, the relationship between the steps is not yet clear.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 5015032      PMCID: PMC1665693          DOI: 10.1111/j.1476-5381.1972.tb07244.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  31 in total

1.  PLATELET CLUMPING IN VITRO.

Authors:  J R MITCHELL; A A SHARP
Journal:  Br J Haematol       Date:  1964-01       Impact factor: 6.998

2.  THE INITIAL CHANGES IN PLATELET MORPHOLOGY FOLLOWING THE ADDITION OF ADENOSINE DIPHOSPHATE.

Authors:  D C MACMILLAN; M F OLIVER
Journal:  J Atheroscler Res       Date:  1965 Jul-Aug

3.  Changes in the distribution of phosphorus in platelet-rich plasma during clotting.

Authors:  G V BORN
Journal:  Biochem J       Date:  1958-04       Impact factor: 3.857

Review 4.  Metabolism, transfer and storage of 5-hydroxytryptamine in blood platelets.

Authors:  A Pletscher
Journal:  Br J Pharmacol Chemother       Date:  1968-01

5.  Inhibition of serotonin-induced platelet aggregation in relation to thrombus production.

Authors:  F Michal; F Penglis
Journal:  J Pharmacol Exp Ther       Date:  1969-04       Impact factor: 4.030

6.  D-receptor for serotonin on blood platelets.

Authors:  F Michal
Journal:  Nature       Date:  1969-03-29       Impact factor: 49.962

7.  Platelet aggregation in mammalians (human, rat, rabbit, guinea-pig, horse, dog). A comparative study.

Authors:  Z Sinakos; J P Caen
Journal:  Thromb Diath Haemorrh       Date:  1967-02-28

8.  Sodium-dependent accumulation of 5-hydroxytryptamine by rat blood platelets.

Authors:  J M Sneddon
Journal:  Br J Pharmacol       Date:  1969-11       Impact factor: 8.739

9.  Uptake, metabolism and release of (3H)-adrenaline by human platelets.

Authors:  G V Born; J B Smith
Journal:  Br J Pharmacol       Date:  1970-08       Impact factor: 8.739

10.  A sensitive method for the assay of 5-hydroxytryptamine.

Authors:  J R VANE
Journal:  Br J Pharmacol Chemother       Date:  1957-09
View more
  30 in total

1.  Proceedings: Time-dependent potentiation and inhibition by 5-hydroxytryptamine of platelet aggregation induced by ADP.

Authors:  F Michal; M Motamed
Journal:  Br J Pharmacol       Date:  1975-06       Impact factor: 8.739

2.  Evidence for various tryptamines and related compounds acting as substrates of the platelet 5-hydroxytryptamine transporter.

Authors:  R Wölfel; K H Graefe
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-02       Impact factor: 3.000

3.  Editor's page: fundamentals in neurocardiology: the brain-platelet-coronary artery interface.

Authors:  Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2008-07-20       Impact factor: 2.300

4.  The actions of flupenthixol upon 5-hydroxytryptamine-induced aggregation and the uptake of 5-hydroxytryptamine and dopamine by human blood platelets.

Authors:  D J Boullin; R P Grimes; M W Orr
Journal:  Br J Pharmacol       Date:  1975-12       Impact factor: 8.739

5.  Characterization of receptors mediating 5-hydroxytryptamine- and catecholamine-induced platelet aggregation, assessed by the actions of alpha- and beta-blockers, butyrophenones, 5-HT antagonists and chlorpromazine.

Authors:  D J Boullin; P A Glenton
Journal:  Br J Pharmacol       Date:  1978-04       Impact factor: 8.739

Review 6.  Platelets and neurobiological research.

Authors:  G V Born
Journal:  Experientia       Date:  1988-02-15

7.  Structure-activity relations for the inhibition of 5-hydroxytryptamine uptake by tricyclic antidepressants into synaptosomes from serotoninergic neurones in rat brain homogenates.

Authors:  A S Horn; R C Trace
Journal:  Br J Pharmacol       Date:  1974-07       Impact factor: 8.739

8.  Effects of imipramine and desipramine on responses of single cortical neurones to noradrenaline and 5-hydroxytryptamine.

Authors:  C M Bradshaw; M H Roberts; E Szabadi
Journal:  Br J Pharmacol       Date:  1974-11       Impact factor: 8.739

9.  The 5-hydroxytryptamine-like actions of 5,6-dihydroxytryptamine.

Authors:  F Barzaghi; H R Baumgartner; M Carruba; P Mantegazza; A Pletscher
Journal:  Br J Pharmacol       Date:  1973-06       Impact factor: 8.739

Review 10.  Tryptamine: a metabolite of tryptophan implicated in various neuropsychiatric disorders.

Authors:  D D Mousseau
Journal:  Metab Brain Dis       Date:  1993-03       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.